Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DRIO 
DarioHealth Corp (DRIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/07/2025: DRIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.25
1 Year Target Price $22.25
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.92% | Avg. Invested days 27 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.60M USD | Price to earnings Ratio - | 1Y Target Price 22.25 |
Price to earnings Ratio - | 1Y Target Price 22.25 | ||
Volume (30-day avg) 4 | Beta 1.07 | 52 Weeks Range 5.93 - 31.00 | Updated Date 11/9/2025 |
52 Weeks Range 5.93 - 31.00 | Updated Date 11/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-17 | When - | Estimate -0.1933 | Actual - |
Profitability
Profit Margin -162.73% | Operating Margin (TTM) -171.35% |
Management Effectiveness
Return on Assets (TTM) -22.55% | Return on Equity (TTM) -66.92% |
Valuation
Trailing PE - | Forward PE 10.59 | Enterprise Value 107907826 | Price to Sales(TTM) 3.12 |
Enterprise Value 107907826 | Price to Sales(TTM) 3.12 | ||
Enterprise Value to Revenue 3.97 | Enterprise Value to EBITDA -0.59 | Shares Outstanding 6768184 | Shares Floating 2108761 |
Shares Outstanding 6768184 | Shares Floating 2108761 | ||
Percent Insiders 18.27 | Percent Institutions 9.66 |
Upturn AI SWOT
DarioHealth Corp
Company Overview
History and Background
DarioHealth Corp. (formerly LabStyle Innovations) was founded in 2011. It initially focused on developing and marketing a digital diabetes management solution. Over time, it has evolved into a broader digital health company offering solutions for multiple chronic conditions.
Core Business Areas
- Digital Therapeutics: Provides digital health solutions for chronic conditions such as diabetes, hypertension, weight management, musculoskeletal disorders, and behavioral health. This includes a personalized, AI-powered platform with connected devices and coaching.
- Business-to-Business (B2B) Solutions: Offers its platform and services to employers, health plans, and providers, enabling them to provide comprehensive chronic condition management to their members and patients.
Leadership and Structure
The leadership team consists of CEO Erez Raphael, CFO Rick Anderson, and other key executives. The company operates with a functional organizational structure, with departments focusing on product development, sales and marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Dario Blood Glucose Monitoring System: A smart blood glucose meter connected to a mobile app for real-time data tracking and insights. Market share data is not publicly available. Competitors include Dexcom (DXCM), Abbott (ABT), and Roche.
- Market Share Data (%):
- Dario Digital Therapeutics Platform: A comprehensive platform for managing multiple chronic conditions, including diabetes, hypertension, weight management, musculoskeletal disorders, and behavioral health. Dario utilizes connected devices, personalized coaching, and AI to drive engagement and outcomes. Market share data is not publicly available as the market is relatively new. Competitors include Teladoc Health (TDOC) through its Livongo acquisition, Omada Health, and Vida Health.
- Market Share Data (%):
Market Dynamics
Industry Overview
The digital health market is experiencing rapid growth, driven by increasing prevalence of chronic diseases, rising healthcare costs, and advancements in technology. The market is competitive, with numerous companies offering various digital health solutions.
Positioning
DarioHealth Corp. is positioned as a comprehensive digital health platform for multiple chronic conditions, differentiating itself through its personalized, AI-powered approach and integrated platform. They compete in a growing market with both larger established players and smaller niche providers.
Total Addressable Market (TAM)
The estimated total addressable market (TAM) for digital chronic disease management is significant, potentially reaching hundreds of billions of dollars globally. DarioHealth is positioned to capture a portion of this TAM by expanding its platform and partnerships. The TAM is difficult to quantify precisely, but analysts project significant growth in the coming years.
Upturn SWOT Analysis
Strengths
- Comprehensive digital health platform
- Personalized, AI-powered approach
- Integrated connected devices and coaching
- Focus on multiple chronic conditions
- B2B sales channel
Weaknesses
- Limited brand recognition compared to larger players
- Reliance on partnerships for distribution
- Profitability challenges
- High marketing and sales expenses
- Relatively small market capitalization
Opportunities
- Expanding partnerships with employers and health plans
- Geographic expansion
- New product development and platform enhancements
- Increasing adoption of digital health solutions
- Potential for strategic acquisitions
Threats
- Intense competition
- Regulatory changes
- Data privacy and security concerns
- Reimbursement challenges
- Economic downturn affecting employer spending
Competitors and Market Share
Key Competitors
- TDOC
- OMAD
- LVGO
- ABT
- DXCM
Competitive Landscape
DarioHealth Corp. competes with larger, more established players in the digital health market. Its advantages include its comprehensive platform, personalized approach, and focus on multiple chronic conditions. Disadvantages include limited brand recognition and reliance on partnerships.
Major Acquisitions
PsychoSolutions
- Year: 2021
- Acquisition Price (USD millions): 6
- Strategic Rationale: Expanded behavioral health capabilities and broadened DarioHealth's platform offerings.
Upright Technologies Ltd.
- Year: 2021
- Acquisition Price (USD millions): 31
- Strategic Rationale: Enhanced musculoskeletal (MSK) solution through wearable technology, posture analysis and personalized training programs.
Growth Trajectory and Initiatives
Historical Growth: DarioHealth Corp. has experienced revenue growth in recent years, driven by increased adoption of its digital health solutions and expansion of its B2B partnerships.
Future Projections: Future growth is projected to be driven by continued expansion of the platform, new product development, and strategic partnerships. Analyst estimates vary, but generally indicate continued revenue growth in the coming years.
Recent Initiatives: Recent initiatives include new partnerships with employers and health plans, expansion of the platform to address additional chronic conditions, and strategic acquisitions to enhance its capabilities.
Summary
DarioHealth is a growing digital health company with a comprehensive platform and a focus on chronic conditions. While it has strengths in its technology and B2B partnerships, it faces challenges related to profitability and competition. Strategic initiatives and market expansion are crucial for future success, as are managing costs and maintaining a competitive edge.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DarioHealth Corp
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-10-06 | CEO & Director Mr. Erez Raphael | ||
Sector Healthcare | Industry Health Information Services | Full time employees 196 | Website https://www.dariohealth.com |
Full time employees 196 | Website https://www.dariohealth.com | ||
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1. It also provides bundled full-suite or partial-suite subscriptions. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.